Purpose: Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …

Purpose: This retrospective study was undertaken to investigate the impact of initial gefitinib
or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of …

Gefitinib—a specific inhibitor of epidermal growth factor receptor (EGFR)-associated tyrosine
kinase—has demonstrated efficacy in a subgroup of patients with non-small-cell lung …

Objectives The purpose of this study was to examine the impact of EGFR mutations on the
incidence of brain metastases in patients with advanced non-small cell lung cancer …

Brain metastases are a common and devastating consequence of disease progression in
patients with non–small cell lung cancer (NSCLC). The epidermal growth factor receptor …

Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …

Lung cancer is the leading cause of cancer death in men and women worldwide. Brain
metastasis (BMs) of non-small cell lung cancer (NSCLC) is the most important cause of …

Introduction The efficacy of high-dose (1250 mg/d) gefitinib for the treatment of
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …

A small subset of patients with nonsmall cell lung cancer (NSCLC) harbors mutations in the
epidermal growth factor receptor (EGFR) that predict unique sensitivity to EGFR tyrosine …

The clinical efficacy of gefitinib, a tyrosine kinase inhibitor of epidermal growth factor
receptor (EGFR), on brain metastases (BMs) from non–small-cell lung cancer (NSCLC) was …